Last Week, OptimizeRx Corporation (OPRX) Recorded A Gain Of $50.68


As of Friday close, OptimizeRx Corporation’s (NASDAQ:OPRX) stock was down -$0.18, moving down -1.40 percent to $12.65. The average number of shares traded per day over the past five days has been 1,099,640 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.44 fall in that time frame. In the last twenty days, the average volume was 497,545, while in the previous 50 days, it was 275,752.

Since last month, OPRX stock retreated -30.72%. Shares of the company fell to $12.20 on 03/16/23, the lowest level in the past month. A 52-week high of $43.28 was reached on 02/03/23 after having rallying from a 52-week low of $12.20. Since the beginning of this year, OPRX’s stock price has dropped by -24.70% or -$4.15, and marked a new high 4 times. However, the stock has declined by -70.77% since its 52-week high.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


OPRX stock investors should be aware that OptimizeRx Corporation (OPRX) stock had its last reported insider trading activity 204 days ago on Aug 26. Odence-Ford Marion, the General Counsel and CCO of the company, purchased of 1,000 shares for $15.75 on Aug 26. It resulted in a $15,750 investment by the insider. FEBBO WILLIAM J added 10,700 shares at an average price of $15.29 on Aug 22. The insider now owns 461,772 shares following the transaction. On Aug 19, Director Lang James Paul bought 6,000 shares at $16.45 apiece. The transaction was valued at $98,723.

Valuation Metrics

The stock’s beta is 1.05. Besides these, the trailing price-to-sales (P/S) ratio of 3.81, the price-to-book (PB) ratio of 1.75, and the price-to-cash flow ratio of 74.32 may also be considered.

Financial Health

In the three months ended December 30, OptimizeRx Corporation’s quick ratio stood at 16.20, while its current ratio was 16.20, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 62.40% percent. In the year ended December 30, operating margins totaled -11.30%. Based on annual data, OPRX earned $38.97 million in gross profit and brought in $62.45 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 0.30%. Return on equity (ROE) for the past 12 months was -5.20%.

OPRX’s revenue fell -3.36% to $15.09 million during the quarter, while net income inched up to $19.65 million. While analysts expected OptimizeRx Corporation to report $0.24 quarterly earnings, the actual figure was $0.25 per share, beating the consensus estimate by 4.20%. The liabilities of OptimizeRx Corporation were 8.54 million at the end of its most recent quarter ended December 30, and its total debt was $0.23 million.

Technical Picture

This quick technical analysis looks at OptimizeRx Corporation’s (OPRX) price momentum. With a historical volatility rate of 80.82%, the RSI 9-day stood at 25.32% on 17 March.

With respect to its five-day moving average, the current OptimizeRx Corporation price is down by -3.36% percent or -$0.44. At present, OPRX shares trade -29.92% below its 20-day simple moving average and -16.00% percent below its 100-day simple moving average. However, the stock is currently trading approximately -32.86% below its SMA50 and -50.55% below its SMA200.

Stochastic coefficient K was 9.04% and Stochastic coefficient D was 10.90%, while ATR was 1.12. Given the Stochastic reading of 6.98% for the 14-day period, the RSI (14) reading has been calculated as 29.09%. As of today, the MACD Oscillator reading stands at -1.06, while the 14-day reading stands at -2.46.

Analyst Ratings

OptimizeRx Corporation (OPRX) has been rated Buy by analysts. According to 0 brokerage firms, OPRX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate OptimizeRx Corporation stock as buy, with 7 recommending it as overweight.

With a median target price of $18.00, the current consensus forecast for the stock is $16.00 – $31.00. Based on these forecasts, analysts predict OptimizeRx Corporation (OPRX) will achieve an average price target of $21.50.


Please enter your comment!
Please enter your name here